A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Seltorexant (Primary)
- Indications Insomnia; Major depressive disorder
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 22 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Feb 2016 Top-line results published in a Minerva Neurosciences media release.
- 01 Feb 2016 Status changed from not yet recruiting to recruiting, according to a Minerva Neurosciences media release.